Objective: Several small case series identified KCTD7 mutations in patients with a rare autosomal recessive disorder designated progressive myoclonic epilepsy (EPM3) and neuronal ceroid lipofuscinosis (CLN14). Despite the name KCTD (potassium channel tetramerization domain), KCTD protein family members lack predicted channel domains. We sought to translate insight gained from yeast studies to uncover disease mechanisms associated with deficiencies in KCTD7 of unknown function. Methods: Novel KCTD7 variants in new and published patients were assessed for disease causality using genetic analyses, cell-based functional assays of patient fibroblasts and knockout yeast, and electron microscopy of patient samples. Results: Patients with KCTD7 mutations can exhibit movement disorders or developmental regression before seizure onset, and are distinguished from similar disorders by an earlier age of onset. Although most published KCTD7 patient variants were excluded from a genome sequence database of normal human variations, most newly identified patient variants are present in this database, potentially challenging disease causality. However, genetic analysis and impaired biochemical interactions with cullin 3 support a causal role for patient KCTD7 variants, suggesting deleterious alleles of KCTD7 and other rare disease variants may be underestimated. Both patient-derived fibroblasts and yeast lacking Whi2 with sequence similarity to KCTD7 have impaired autophagy consistent with brain pathology. Interpretation: Biallelic KCTD7 mutations define a neurodegenerative disorder with lipofuscin and lipid droplet accumulation but without defining features of neuronal ceroid lipofuscinosis or lysosomal storage disorders. KCTD7 deficiency appears to cause an underlying autophagy-lysosome defect conserved in yeast, thereby assigning a biological role for KCTD7. ANN NEUROL 2018; 84:774-788 A utism, schizophrenia, dystonia, epilepsy, and other disorders have been linked to several members of the gene family KCTD (potassium channel tetramerization domain). [1] [2] [3] [4] All KCTD family proteins have an Nterminal BTB domain that is most similar in sequence to voltage-gated potassium channel tetramerization (T1/BTB) domains, hence the name KCTD. 5 However, KCTD proteins appear unlikely to form channels, as they lack predicted transmembrane domains and any direct interaction with potassium channels remains uncertain. Although KCTDs could indirectly alter channel properties, the gene name is potentially misleading and has caused some diagnostic challenges with implied treatments for channelopathies. 6 Patients with KCTD7 mutations have been diagnosed with progressive myoclonic epilepsy (EPM3), 4, [7] [8] [9] [10] [11] [12] neuronal ceroid lipofuscinosis 14 (CLN14), 13 or opsoclonus-myoclonus syndrome (OMS). 14 We sought to further define the clinical syndrome resulting from KCTD7 deficiency, to distinguish deleterious from normal variants in the general population, and to assign a function to the uncharacterized KCTD7 protein based on insights gained from our studies of the related protein in yeast, Whi2. KCTD family proteins are relatively uncharacterized, but one common theme has begun to emerge. A subset of KCTD family proteins may be components of cullin 3 (CUL3) ubiquitin ligase complexes. 15 CUL3 uses BTBcontaining adaptor proteins from other protein families to recruit cargo proteins for ubiquitination. Several KCTD family proteins including KCTD7 have been reported to bind CUL3, 13, 16 consistent with structure modeling for other KCTDs. 15 In this capacity as potential cargo adaptors, several other KCTD family proteins have been suggested to target specific cargo proteins for degradation, 1 although most await confirmation. A similar role for KCTD7 is consistent with lysosome pathway defects in several other EPM and CLN disorders 17, 18 and other neurodegenerative processes. 19 However, the molecular and cellular consequences of KCTD7 deficiency are not known. This project was prompted by our genome-wide yeast genetic screen that uncovered the KCTD-like BTBcontaining protein Whi2 of Saccharomyces cerevisiae.
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Yeast Whi2 is reportedly a general stress response factor 20 and has a contested role in mitophagy. 21, 22 Yeast Whi2 and autophagy regulator Atg6 (human Beclin 1) were identified in our screen for factors required to respond to low amino acid availability, 5,23 a condition known to induce catabolic processes such as autophagy in yeast and mammals. 24 Because yeast Whi2 shares sequence similarity and a common domain architecture with human KCTD proteins, 5 we sought to gain new insight into the disease mechanisms due to KCTD7 mutations. We found that both yeast Whi2 and human KCTD7 are required for normal autophagy in low nutrients, further supported by the accumulation of lipid bodies, defective mitochondria, and abnormal autolysosomes in patient cells.
Patients and Methods

Patient Data Collection
Clinicians were provided a form for deidentified data (Supplementary Table 1 , institutional review board exempt status).
Electron Microscopy
Patient fibroblasts were fixed in 2.5% glutaraldehyde (electron microscopy grade; Electron Microscopy Sciences, Hatfield, PA) in 0.1M sodium cacodylate buffer (pH 7.4) for 1 hour at room temperature, and processed by the Yale University Electron Microscopy Core as described. with protease inhibitor cocktail (Thermo Fisher Scientific), and heated to 100 C for 10 minutes before separation by 12% SDS-polyacrylamide gel electrophoresis (PAGE) and transfer to polyvinylidene difluoride (PVDF).
Immunoblots were performed using antibodies for LC3B (Cell Signaling Technology #2775 or 3868, 1:1,000) and actin (MP Biomedicals, Santa Ana, CA #691001, 1:10,000), visualized using a Bio-Rad Laboratories (Hercules, CA) ChemiDoc MP system, and analyzed with Image Lab 5.0 software (Bio-Rad Laboratories).
Immunofluorescence Microscopy
Kyoto HeLa cells (American Type Culture Collection, Manassas, VA) were grown on 12mm glass cover slips in DMEM, 10% FBS plus pen/strep, and transfected the next day with 150ng total DNA using jetPRIME (VWR, Radnor, PA). At 16 to 18 hours posttransfection, cells were fixed for 10 minutes with 4% formaldehyde (Polysciences, Warrington, PA), permeabilized with 0.2% Triton X-100 in PBS, immunostained, mounted (Prolong Gold, Life Technologies), and viewed with a Zeiss (Oberkochen, Germany) AxioImager M2 (×60 Olympus [Tokyo, Japan] objective), Hamamatsu Photonics (Hamamatsu, Japan) Orca R2 camera, and Volocity software (PerkinElmer, Waltham, MA), or an Applied Precision (Issaquah, WA) DeltaVision microscope and software (×60 Olympus objective) with a Hamamatsu Photonics camera.
Coimmunoprecipitations N-terminal 3HA/3Flag-KCTD7 and 6Myc-cullin 3 (CUL3) expression vectors were transiently transfected into HEK-293 cells using BioT (Bioland Scientific, Paramount, CA) for 2 days. Cells were lysed in native lysis buffer containing 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride, pepstatin, and leupeptin, and rotated for 60 minutes at 4 C, and remaining insoluble material was removed by centrifugation. Samples were normalized (A280nm) and rotated at 4 C for 2 hours with preequilibrated EZview Red antihemagglutinin (anti-HA) or anti-FLAG affinity gel (Sigma). Beads were washed 4 times in the same buffer, and proteins were eluted by boiling in SDS-PAGE sample buffer. Whole cell lysates and anti-HA precipitates were separated by SDS-PAGE, transferred to PVDF membranes, and probed with antibodies against FLAG (F1804, Sigma), HA (12CA5; Roche, Basel, Switzerland), or α-tubulin (HRP-66031; Proteintech Group, Rosemont, IL) and horseradish peroxidase-conjugated secondary antibodies. Proteins were detected with ECL Western Blotting Substrate (Pierce, Rockford, IL), SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific), and autoradiography.
Yeast Autophagy Assays
Yeast strains (BY4741) transformed with autophagy reporter plasmids were grown overnight in synthetic SC CSH medium, refed for 1 hour in fresh SC CSH medium at 1 OD 600 /ml, washed once, and switched to low amino acid medium SC ME as described. 5 Cells corresponding to 2 OD 600 units were collected and lysed for immunoblot analysis. 5 
Results
To better define the disorder caused by KCTD7 mutations, we identified 18 novel mutations in 15 patients (11 families) from several sequencing centers and institutions ( Fig 1A) . A total of 30 novel KCTD7 variants from 37 new and published patients can be grouped into 3 protein regions, the N-terminal BTB domain, a C-terminal cluster, and a less defined middle region ( Fig 1B) . All 37 patients have homozygous or compound heterozygous variants in KCTD7 (23 missense, 3 stop-gain, and 4 frameshifts). However, their association with disease does not constitute proof of pathogenicity for each patient variant. To address this point, we first characterized the clinical syndrome.
KCTD7 Mutations Are Associated with a Progressive Neurodegenerative Disorder
Overt seizures mark the recorded age of onset for 76% of KCTD7 patients, many with accompanying developmental delays and movement disorders, predominantly ataxia, tremors, and dyskinesia ( Fig 1A) . The remaining 24% first develop movement disorders or developmental delays prior to seizure onset. Genetic testing for KCTD7 variants at earlier ages could potentially identify more patients with movement disorders before seizure onset. Other prominent clinical features include the loss of normal developmental milestones achieved in early childhood, difficulty walking, loss of speech and fine motor skills, and severe cognitive decline. Although electroencephalographic findings are often positive, brain magnetic resonance imaging is typically normal at onset but may detect diffuse or focal brain atrophy after disease progression, for example as observed for new Patient 1 (T64A/R211X) but not for new Patient 2 (see Supplementary Table 1) . Patient 2 underwent a complete corpus callosotomy at age 6.9 years, and was seizure-free for at least 18 months, with some improvement in motor control. All patients progressed to develop myoclonic epilepsy, and all with available data developed movement disorders. Most become wheelchair-bound and nonverbal, and 6 of 37 died at age 3 to 18 years ( Fig 1A, asterisks) . The few ambulatory patients now in their 20s (Patients 9, 10, and 19) have significant motor and cognitive deficits and exhibit autism, obsessive-compulsive disorder, or schizophrenia, in addition to epilepsy (see Supplementary Table 1) .
Early Onset without Retinal Degeneration Distinguishes KCTD7 Patients Distinguishing KCTD7/EPM3 patients from related disorders is the early age of onset, consistent with published case reports (Fig 2) . Average onset age for all 37 patients is 17 months, range = 5 to 24 months except one of a sibling pair lacking C-terminal residue W289 with disease onset reported at 36 months (Patient 37; Fig 1A) . No gender bias is present for incidence (49% males), although males tended to be diagnosed at a younger age (mean onset = 15.1 months for males, 19.1 months for females). This early onset age for KCTD7/EPM3 patients does not overlap with other early onset myoclonic epilepsies (EPM1A, EPM2, EPM4), with the exception of infantile CLN1 (onset at 6-24 months) caused by mutations in lysosomal enzyme PPT1 (Fig 2) . 26, 27 However, KCTD7
patients uniformly lacked the characteristic CLN1-associated retinal abnormalities at onset and associated blindness ( Fig 1A) . 18, 26 These findings shift the age downward for considering the diagnosis of EPM3, which is typically diagnosed in childhood or adolescence. KCTD7 patients are also distinguished from other related disorders. They have more severe cognitive decline and earlier onset than patients with a BTB domain variant in Kv3.1/ KCNC1 (onset age = 3-15 years), 28 but a later average onset than infantile spasms due to autosomal dominant mutations in DNM1 (onset typically at 4-7 months) or autosomal recessive mutations in TBC1D24 (GTPaseactivating ARF6-binding protein) that cause pleiotropic neurologic disorders with myoclonic seizures (median onset at 2-3 months, often at birth; Fig 2) .
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Prevalence Table 2 ). The gene damage index GDI-Phred value for KCTD7 (1.235, medium damage prediction) and the selective pressure assessed by the McDonaldKreitman neutrality index (0.004, moderate purifying) 31 are also consistent with a monogenic autosomal recessive disease with complete penetrance. However, cautious causality assignments may still be warranted for specific KCTD7 variants given 500 to 20,000 protein-altering variants per individual. 32 If all 30 KCTD7 variants are disease-causing, each is expected to be rare in the general population. In an effort to catalog normal genetic variation in healthy individuals, the exome aggregation consortium ExAC database of 60,000 unrelated healthy individuals excluded cancer genomes and cohorts with severe pediatric diseases. 32 Thus, most of the KCTD7 patient variants listed in ExAC (10 of 14) are from previously unpublished patients (see Supplementary Table 2) . Among all KCTD7 variant alleles identified, T64A (Patient 1, T64A/R211X) is the most frequent in ExAC, where it is reported in 9 individuals (0.010% to 0.019% allele frequency in European and African populations, respectively), and in 16 heterozygous individuals in the aggregate gnomAD database of 130,000 individuals (Fig 3B) . However, this frequency is still rare and to date no homozygotes for any amino acid change in KCTD7 has been reported in healthy individuals. 32 27 sialidosis/mucolipidosis-I from https://emedicine.medscape.com/article/948704-overview, and for KCTD7/EPM3 from Figure 1A . [Color figure can be viewed at www.annalsofneurology.org] structures in the nucleus (Fig 4A) . Taking advantage of these elaborate structures to distinguish the effects of patient mutations, we found that expression of T64A (1-149) abolishes these cytoplasmic structures and instead localizes predominantly in a nuclear ball-and-stick pattern. Two other BTB domain mutations from published patients cause other distinguishable morphologies. L108M (Patients 11-13) increases the occurrence of minicircles at filament termini, and D115Y (Patient 15, lacking family genetics) causes massive filamentlike structures, which is likely a cause or consequence of protein stabilization (Fig 4B) . When coexpressed with CUL3, an E3 ubiquitin ligase component reported to bind KCTD7, 13, 16 both wild type KCTD7 and D115Y, and to a lesser extent L108M, were capable of recruiting CUL3 from its more diffuse localization to KCTD7 structures (Fig 4C,D) . In contrast, the T64A mutant only rarely colocalized with CUL3 in fuzzy nuclear spots. Thus T64A, L108M and D115Y, are likely to alter KCTD7 function, consistent with functional-effect prediction algorithms. T64A is strongly predicted to be damaging by PolyPhen2, SIFT, and PROVEAN, and L108M and D115Y are predicted to be damaging by two of these algorithms (see Supplementary Table 2 ). Providing further evidence that patient mutations can alter interactions with CUL3, coimmunoprecipitation assays revealed that the N-terminal BTB-containing region but not the C-terminus of KCTD7 is required for CUL3 interaction (Fig 4E) , consistent with a role for KCTD7 as a CUL3 adaptor. Furthermore, the patient BTB domain mutations tested in full-length KCTD7 (R70W, L108M, and likely R84Q) impair binding to CUL3 (Fig 4E) .
The only patients predicted to have functionally benign variants by PolyPhen2, SIFT, and PROVEAN also have less debilitating disease (sibling Patients 9/10; see Supplementary Table 1 ). However, their nucleotide change corresponding to G105E (c.314G>A) is located at the exon2-intron junction and is predicted to affect normal splicing (SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, and Human Splicing Finder). Other KCTD7 patient variants have discordant functional predictions between the different algorithms (see Supplementary Table 2 ), reinforcing that pathogenicity predictions are inherently limited without 3-dimensional structures and functional biochemical assays.
KCTD7 Heterozygosity in Other Neurological Disorders
We also identified 16 novel heterozygous KCTD7 variants in 18 additional unrelated individuals with phenotypes related to biallelic KCTD7EPM3 patients. These heterozygous patients with predominantly unsolved disease etiologies (mean onset age = 8.6 years) have neurological phenotypes including developmental delays, seizures, disease progression, movement disorders, and/or intellectual disabilities (see Supplementary Table 3 ). Only 1 of these 18 variants occurs more frequently than T64A in the population (Y86H occurs in 53 normal heterozygotes). 32 Two of the 18 are also found in EPM3 patients with biallelic KCTD7 mutations, R121L and R153H. However, any role for heterozygous KCTD7 variants as genetic modifiers is not known. Conversely, we cannot rule out the possibility that non-KCTD7 variants act as genetic modifiers of more complex traits affecting onset age or other variations between biallelic KCTD7 patients. Patient 9 (G105E/ G114E) also has a heterozygous pathogenic variant in GALC that is reported in patients with autosomal recessive, late onset neurodegenerative Krabbe disease, and a heterozygous variant of unknown significance (VUS) in ARID1A, a conserved gene responsible for autosomal dominant intellectual disability (Coffin-Siris syndrome). Patient 14 (R112C/R112C) has mutations in 3 other genes linked to epilepsy, including a homozygous predicted damaging VUS in the glutamate receptor GRIN2A. These and other noted variants in biallelic KCTD7-deficient patients (see Supplementary Table 1) are currently not predicted to be disease-related, but only on the basis that all were inherited from one heterozygous parent and therefore insufficient to cause disease.
Evidence for Lysosome-Pathway Defects without Characteristic Neuronal Ceroid Lipofuscinosis
Electron microscopy analysis of a frontal lobe brain biopsy from new Patient 1 (T64A/R211X) at age 8 years revealed neuronal pathology (Fig 5) that was absent in the brain of a neurologically normal 6.7-year-old child (not shown). The prominent brain pathology in Patient 1 was the electron-dense lipofuscin (lysosomes). Similar structures are commonly observed in normal aging brain but not in children. A potential feature of KCTD7 brain lipofuscin is the late autophagosomelike structures engorged with both electron-dense lysosomes and electron-lucent structures presumed to be lipid droplets. Soft lipid droplets are compressed between lysosomes or bulge against a delimiting membrane. Others have observed similar structures in autophagy-deficient cells, and in cells overfed with oleic acid. 34 The persistence of lipid droplets in brain tissue could potentially reflect an underlying defect related to lipophagy, a form of autophagy that is required for utilization of lipid stores as an energy source and that requires components of the autophagy pathway. 35 Biallelic KCTD7 mutations that define a diagnosis of EPM3, also define the diagnosis of neuronal ceroid lipofuscinosis 14 (CLN14) based on a study of Patient 24 (R184C/R184C). 13 That study reported characteristic ultrastructural features of fingerprintlike profiles and granular osmiophilic deposits in fibroblasts and neurons from a skin biopsy and in lymphocytes. 13 Cultured skin fibroblasts naturally lack some of the lysosomal substrates enriched in the brain such as specific glycosphingolipids, and are therefore not expected to reveal some brain pathologies. However, fibroblast cultures are useful for evaluating other autophagosomelysosome functions and ultrastructure. In contrast to an age-and passage-matched control, prominent features of early passage skin-derived fibroblast cultures from Patient 3 and Patient 4 with BTB domain mutations include the supernumerary lipid droplets often in close proximity to mitochondria and endoplasmic reticulum (Fig 6A) . Some lipid droplets appeared to be engulfed in membranebound structures (see Fig 6A, arrowheads) , reminiscent of the lipid droplets in patient brain, possibly suggesting a stalled catabolic process.
Other prominent features that distinguish both patient fibroblasts from age-and passage-matched control fibroblasts include hybrid structures resembling late singlemembrane or partially double-membrane autolysosomes. 37 These hybrid structures contain local electron densities typical of lysosomes (Fig 6B, black arrows) that are associated with larger autophagosome-like structures containing residual undegraded material (Fig 6B, white arrows) and 774 Volume 84, No. 5 occasional electron dense lipid whirls. Similar hybrid structures are also characteristics of diverse neurodegenerative disorders including mucolipidosis type IV, Alzheimer disease, CLN types, and autophagy-deficient cell lines. [37] [38] [39] Although mitochondrial organelles were not sufficiently preserved in patient biopsy preparations, most cultured fibroblasts from both patients contained a fraction of mitochondria with internal, closed double membrane structures presumed to reflect cristae malformations (Fig 6C) . These malformations are somewhat reminiscent of mitochondria in mitofilin-deficient cells with concentric cristae. 40 Ultrastructural abnormalities were prevalent in patient cells but absent in control cells (Fig 6D) . The apparent accumulation of several abnormal organelles in patient-derived fibroblasts and in a brain biopsy is consistent with a defect in the phagolysosome pathway.
Conserved Autophagy Defects as a Potential Mechanism of Disease Pathogenesis
We initiated this KCTD7 project based on insights gained from studying the poorly characterized yeast protein Whi2, which shares sequence similarity with KCTD7 and harbors a homologous BTB structural domain. 5 Yeast lacking WHI2 are sensitive to multiple cell stresses and fail to halt the cell cycle in response to low amino acid levels in the media, conditions known to induce autophagy. 5, 20, 23 Taken together with our ultrastructural findings in patient samples, we asked whether whi2-deficient yeast have a general autophagy defect using an established reporter for yeast Atg8, 41 homolog of mammalian autophagy marker LC3. In low amino acid medium, the autophagy-responsive ATG8 promoter is induced to express the reporter, and during autophagy flux undergoes lysosomal/vacuolar processing that cleaves the protease-sensitive Atg8 moiety from the more stable GFP protein in wild-type cells. 41 In striking contrast to wild type, whi2-deletion strains are profoundly defective for autophagy induction and flux (Fig 7A) . Similar but less dramatic results were obtained with an autophagy flux-specific reporter expressed by the constitutive PGK promoter, indicating that Whi2 is required for normal autophagy induction and flux after switching to low amino acids (Fig 7B) . This autophagy defect was not due to a general defect in reporter expression or global protein translation, as free GFP expressed via an autophagy-independent promoter (ADH1) was expressed indistinguishably in wild-type and whi2-deficient yeast (Fig 7C) .
To extend these findings from yeast, the skinderived fibroblast lines from Patients 3 and 4 with BTB domain mutations were analyzed for autophagy defects. Endogenous lipidated/mature LC3-II normally accumulates following treatment with chloroquine to inhibit lysosome function that otherwise degrades LC3-II. 42 Consistently, LC3-II accumulated less efficiently in lowpassage patient fibroblasts versus age-and passage-matched controls following chloroquine treatment to assess basal autophagy flux, and when autophagy was induced by withdrawing amino acids and glucose (Fig 8A, B) . Autophagy induced by more severe starvation was also significantly lower in patient fibroblasts assessed by conversion of LC3I to LC3II (Fig 8C) . Thus, both WHI2-deficient yeast and patient cells have a defect in autophagy based on Atg8/LC3 assays following nutrient depletion. To confirm the origins of our fibroblast cell lines, genomic DNA isolated from patient and control cells used in these studies was sequenced, revealing the expected variants for Patients 3 and 4.
The functional consequences of autophagy deficiency were assessed by determining the effects of KCTD7 on neurite outgrowth triggered by serum withdrawal in mouse neuroblastoma N2a cells. The maturation of N2a cells to produce extensive neuronlike processes requires autophagy, as knockdown of conserved Beclin 1/Atg6 blocks neurite extension. 43 We found that partial knockdown of endogenous mouse Kctd7 severely reduces neurite outgrowth triggered by serum withdrawal, indicating a critical role for Kctd7 in neurite maturation (Fig 8D, E) . 14 were not detected, although this was not formally tested. We also did not detect specific neuronal ceroid lipofuscinosis pathology as reported for Patient 24, the founder case for CLN14 designation, although this patient potentially had more severe disease (onset at 8 months, died at 17 years).
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Causality of KCTD7 Variants The low frequency in the general population of each of the 30 unique KCTD7 patient variants, including T64A, and the lack of homozygous patient variants in healthy individuals, 32 indicate that these 30 variants are causal for EPM3/CLN14. This disorder occurs worldwide, and the patients in this study have diverse ancestry (eg, Moroccan, Syrian Sephardi, European, Native American, French Canadian). Genome sequence data from the general population suggest at least 0.05% of healthy unrelated individuals may carry a heterozygous pathogenic KCTD7 variant. 32 The higher than average arginine content of the KCTD7 protein (7.3% vs 4-6%) may contribute to the (A) Immunoblots of wild-type (WT) and whi2 knockout strains of Saccharomyces cerevisiae (BY4741) expressing autophagy reporter fusion protein GFP-Atg8 expressed by autophagyresponsive yeast ATG8/LC3 promoter (pr), before and after switching from high to low amino acid medium as described, 5, 23 probed with 1:1,000 anti-GFP (Santa Cruz Biotechnology, sc-9996), loading control anti-Pgk (Abcam, Cambridge, MA; 113687), and horseradish peroxidaseconjugated secondary antibodies (GE Healthcare, Chicago, IL; 1:20,000). Induction of the ATG8 promoter (total GFP in upper+lower bands relative to PGK loading control) and autophagy flux (protease-resistant free GFP liberated by vacuolar protease-dependent digestion of the Atg8 moiety relative to total GFP) are presented in separate graphs as mean ± standard deviation (SD) for 3 independent experiments with/without switching to low amino acids. (B) Experiment and analysis as described for A except using the constitutive PGK pr to express the GFP-Atg8 autophagy reporter. Results are presented as mean ± SD for 3 independent experiments (2-tailed t test: WT vs Δwhi2, *p < 0.05, **p < 0.005, ***p < 0.001). (C) As described in A except using the transcription/translation control GFP reporter (no Atg8) expressed by the constitutive ADH1 promoter, probed with anti-GFP and loading control antiCdc11 (Novus Biologicals, Littleton, CO; NB100-81019).
[Color figure can be viewed at www.annalsofneurology.org] mutation frequency (12 of 30 variants change an Arg; see Supplementary Table 1) given that arginine codons have the highest proportion of CpG sequences and CpG mutations (affecting DNA methylation) are by far the most prevalent in the population. 32 Additional rare heterozygous KCTD7 variants were identified in 17 additional patients with related yet clinically distinct disorders (see Supplementary Table 3) , although any contribution to disease is unknown. However, when considering the genetic complexities of neurobehavioral disorders such as autism, other genetic modifiers with discernable clinical phenotypes may exist. KCTD7 sibling Patients 9/10 were diagnosed with autism. The KCTD7-related KCTD13 gene at 16p11.2 is thought detected with horseradish peroxidase-conjugated secondary antibodies (GE Healthcare, 1:20,000), developed using ECL-Prime (GE Healthcare). Compare LC3-II levels before versus after 1 hour with 15 μM chloroquine (CQ) (Sigma C6628) or carrier control to assess basal autophagy (arrows). Quantified data are shown on the right, pooling 5757 and 498 control cells versus patient cells from 3 independent experiments, each performed in duplicate or triplicate for each of the 4 cell lines (n = 11 per condition) and presented as the ratio of LC3-II levels ± 15 μM chloroquine after correcting for loading; mean ± standard error (SE), 2-tailed t test, p = 0.00065. (B) Autophagy assay as in A except cells were treated for 3 hours ± glucose, ± amino acids (AA), ± 100nM bafilomycin A1 (Baf) (Enzo, Farmingdale, NY). Quantification on right is presented as mean ± SE of LC3-II levels adjusted to relative loading controls and calculated as the fold change over Control 5757 in full medium for 6 to 8 replicates in 4 independent experiments (2-tailed t test, *p < 0.05). (C) Autophagy assay as in A except cells were incubated in amino acidfree/serum-free Earle balanced salt solution (EBSS; Thermo Fisher Scientific). The change in LC3-II/LC3-I ratios relative to time 0 is presented as mean ± SE for 3 independent experiments; 2-tailed t test* for Control 5757 vs Patient 3 at 2 hours and 3 hours (p = 0.002 and p = 0.018), and Patient 4 (p = 0.023 and p = 0.020, respectively). (D) Light microscopy (Nikon, Tokyo, Japan; TE200) of control and mouse Kctd7-specific shK7.1 shRNA knockdown (TRCN0000069304 transfected with FuGENE or Lipofectamine 2000) in N2a mouse neuroblastoma cells refed ±serum for 48 hours to monitor neurite outgrowths (arrows). (E) Immunoblot confirmation of endogenous Kctd7 knockdown by shK7.1 with 1:1,000 anti-KCTD7 (Abcam ab83237) and anti-HSP90 (BD Biosciences 610419) loading control. Lysates and immunoblots were prepared as described for A, except visualized using Amersham Hyperfilm ECL (GE Healthcare). [Color figure can be viewed at www.annalsofneurology.org] to have a role in a small subset of autism cases. 
Biological and Biochemical Roles for KCTD7
The biochemical function of KCTD7 is not known, and little is understood about the other 24 human family members (KCTD1-21, TNFAIP1, KCNRG, SHKBP1, and BTBD10). Inspired by our finding that yeast Whi2 is required to suppress cell growth in low amino acid conditions, 5, 23 it was reasonable to consider that whi2-deficient yeast were also defective for autophagy induction. Therefore, we tested for an evolutionarily conserved function between Whi2 and KCTD7 in autophagy. We found that both yeast Whi2 and KCTD7 are required for normal basal autophagy and low nutrient-induced autophagy (see Figs 7 and 8) . Both yeast Whi2 and the KCTD7 homolog, KCTD11, were recently shown to suppress TORC1/mTORC1, a known inhibitor of autophagy. 45 The same study failed to detect an effect of KCTD7 on TORC1/mTORC1 activity in yeast and primate COS7 cells. However, a role for KCTD7 in autophagy-lysosome function is consistent with our ultrastructural studies revealing abnormal autophagosome-lysosome structures, mitochondrial cristae, and supernumerary lipid droplets potentially reflecting impaired lipophagy (see Figs 5 and 6) . Related pathologies are observed with aging-related lysosomal dysfunction and progressive decline in chaperone-mediated autophagy rates in late onset Alzheimer disease, 37 perpetuated by oxidation of partially degraded macromolecules derived from mitochondria, glycosphingolipids, and other components in autolysosomes resulting in reactive oxygen species that interact with lysosomal iron. 46 Consistent with our finding of abnormal mitochondrial cristae in patient-derived cells, one study investigated the role of yeast Whi2 in mitophagy (a subtype of autophagy). The authors reported that the spontaneous WHI2 mutation in FIS1 knockout strains, rather than loss of the FIS1 mitochondrial fission gene, causes a defect in the degradation of yeast mitochondrial organelles. 21 However, a subsequent study challenged this conclusion, reporting that mitochondrial fission mediated by FIS1 rather than WHI2 is required for normal mitophagy. 22 Thus, the question remains open. A possible role for KCTD7 in protein turnover is consistent with having an N-terminal BTB domain, where almost half of the patient mutations identified thus far occur (see Fig 1B) , as BTB proteins can serve as adaptor proteins that retrieve substrates for the CUL3 ubiquitin ligase complex. 47 Interestingly, several other KCTD family members were identified in screens for cullin-ARIH1 complex components, 48 consistent with serving as an E3 ubiquitin ligase adaptor. CUL3 has many critical roles in cells, and a role for CUL3 in autophagy has gained recent attention. CUL3 and its BTB-kelch adaptor protein KLHL20 were found to prevent overzealous autophagy by direct ubiquitination and degradation of ULK1, a key upstream positive regulator of autophagy induction. 49 Although KCTD family proteins have not been demonstrated to have a molecular role in autophagy, defective autophagy-lysosome pathways are consistent with their causal roles in neurodegenerative disorders.
